-
Something wrong with this record ?
Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
H. Gbelcová, S. Rimpelová, Z. Knejzlík, J. Šáchová, M. Kolář, H. Strnad, V. Repiská, WC. D'Acunto, T. Ruml, L. Vítek,
Language English Country England, Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2002-12-01
BioMedCentral Open Access
from 2002
Directory of Open Access Journals
from 2002
Free Medical Journals
from 2002
PubMed Central
from 2002
Europe PubMed Central
from 2002
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2002-01-01
Open Access Digital Library
from 2002-01-01
Open Access Digital Library
from 2002-09-01
Medline Complete (EBSCOhost)
from 2002-09-03
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2002
Springer Nature OA/Free Journals
from 2002-12-01
- MeSH
- Anticholesteremic Agents pharmacology MeSH
- Atorvastatin pharmacology MeSH
- Insulin-Secreting Cells drug effects metabolism pathology MeSH
- Indoles pharmacology MeSH
- Mevalonic Acid analogs & derivatives pharmacology MeSH
- Fatty Acids, Monounsaturated pharmacology MeSH
- Humans MeSH
- Lovastatin pharmacology MeSH
- Microarray Analysis MeSH
- Mutation MeSH
- Cell Line, Tumor MeSH
- Polyisoprenyl Phosphates pharmacology MeSH
- Protein Prenylation MeSH
- Proto-Oncogene Proteins p21(ras) genetics metabolism MeSH
- Gene Expression Regulation MeSH
- Recombinant Fusion Proteins genetics metabolism MeSH
- Sesquiterpenes pharmacology MeSH
- Signal Transduction MeSH
- Simvastatin pharmacology MeSH
- Gene Expression Profiling MeSH
- Protein Transport drug effects MeSH
- Green Fluorescent Proteins genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway's intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033445
- 003
- CZ-PrNML
- 005
- 20181015124136.0
- 007
- ta
- 008
- 181008s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12944-017-0641-0 $2 doi
- 035 __
- $a (PubMed)29262834
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gbelcová, Helena $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
- 245 10
- $a Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells / $c H. Gbelcová, S. Rimpelová, Z. Knejzlík, J. Šáchová, M. Kolář, H. Strnad, V. Repiská, WC. D'Acunto, T. Ruml, L. Vítek,
- 520 9_
- $a BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway's intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways.
- 650 _2
- $a anticholesteremika $x farmakologie $7 D000924
- 650 _2
- $a atorvastatin $x farmakologie $7 D000069059
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a kyseliny mastné mononenasycené $x farmakologie $7 D005229
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese $7 D005786
- 650 _2
- $a zelené fluorescenční proteiny $x genetika $x metabolismus $7 D049452
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indoly $x farmakologie $7 D007211
- 650 _2
- $a beta-buňky $x účinky léků $x metabolismus $x patologie $7 D050417
- 650 _2
- $a lovastatin $x farmakologie $7 D008148
- 650 _2
- $a kyselina mevalonová $x analogy a deriváty $x farmakologie $7 D008798
- 650 _2
- $a mikročipová analýza $7 D046228
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a polyisoprenylfosfáty $x farmakologie $7 D011106
- 650 _2
- $a prenylace proteinů $7 D017368
- 650 _2
- $a transport proteinů $x účinky léků $7 D021381
- 650 _2
- $a protoonkogenní proteiny p21(ras) $x genetika $x metabolismus $7 D016283
- 650 _2
- $a rekombinantní fúzní proteiny $x genetika $x metabolismus $7 D011993
- 650 _2
- $a seskviterpeny $x farmakologie $7 D012717
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a simvastatin $x farmakologie $7 D019821
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rimpelová, Silvie $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
- 700 1_
- $a Knejzlík, Zdeněk $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
- 700 1_
- $a Šáchová, Jana $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Kolář, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Strnad, Hynek $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Repiská, Vanda $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a D'Acunto, Walter Cosimo $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
- 700 1_
- $a Ruml, Tomáš $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic. tomas.ruml@vscht.cz.
- 700 1_
- $a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. vitek@cesnet.cz.
- 773 0_
- $w MED00008241 $t Lipids in health and disease $x 1476-511X $g Roč. 16, č. 1 (2017), s. 250
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29262834 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181015124632 $b ABA008
- 999 __
- $a ok $b bmc $g 1340159 $s 1030439
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 16 $c 1 $d 250 $e 20171220 $i 1476-511X $m Lipids in health and disease $n Lipids Health Dis $x MED00008241
- LZP __
- $a Pubmed-20181008